Recent Updates
Recently added Catalysts

TriMaxx Coronary Stent placement

Phase 1

Coronary Artery Disease | Unknown | Cardiovascular |Abbott Laboratories|Last Updated: Oct 15, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment100
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00596661The TRIMAXX Coronary Stent TrialPHASE1 COMPLETED 100May 1, 2004Sep 1, 2005Oct 15, 20083 Brazil, Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Major Adverse Cardiac Events(MACE). MACE defined as Cardiac Death, MI(Q-wave and Non Q-wave) and Rarget Vessel Revascularization (TVR)
30 Days
Secondary Endpoints
Clinical Outcome: MACE
6 months
Clinical Outcome: Ischemia driven TVR
6 months
Clinical Outcome: Ischemia driven Target LesionRevascularization(TLR)
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TRIMAXXEXPERIMENTALTRIMAXX Coronary Stent
Interventions
NameTypeDescription
TriMaxx Coronary Stent placementDEVICEAngioplasty with coronary artery stent placement
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Eligible for catheter based treatment * Single coronary lesion requiring treatment * Lesion is accessible with stent device * Completes informed consent for participation * Stable condition (no symptoms of heart attack within 72 hours prior to treatment) Exclusion Criteria: ...

Countries:BrazilGermany
Unlock Eligibility Criteria